[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dianthus Therapeutics Inc (DNTH)

Dianthus Therapeutics Inc (DNTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,278,937
  • Shares Outstanding, K 54,666
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -162,340 K
  • EBIT $ -218 M
  • EBITDA $ -224 M
  • 60-Month Beta 1.22
  • Price/Sales 3,113.49
  • Price/Cash Flow N/A
  • Price/Book 5.41

Options Overview Details

View History
  • Implied Volatility 56.92% (+2.38%)
  • Historical Volatility 57.29%
  • IV Percentile 9%
  • IV Rank 2.42%
  • IV High 229.28% on 08/25/25
  • IV Low 52.64% on 08/11/26
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 207
  • Volume Avg (30-Day) 207
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 14,164
  • Open Int (30-Day) 12,786
  • Expected Range 115.54 to 115.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.02
  • Number of Estimates 5
  • High Estimate $-0.93
  • Low Estimate $-1.12
  • Prior Year $-0.97
  • Growth Rate Est. (year over year) -5.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.00 +15.54%
on 07/28/26
116.89 -1.15%
on 08/17/26
+9.94 (+9.41%)
since 07/17/26
3-Month
68.85 +67.82%
on 06/10/26
116.89 -1.15%
on 08/17/26
+31.94 (+38.21%)
since 05/18/26
52-Week
20.69 +458.43%
on 08/19/25
116.89 -1.15%
on 08/17/26
+94.58 (+451.24%)
since 08/18/25

Most Recent Stories

More News
Dianthus Therapeutics: The Market May Be Rewarding the Wrong Kind of Discipline

Barchart Research What to Expect from DNTH Earnings DNTH Generated August 5, 2026 Current Price $112.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 5.24% Dianthus Therapeutics: The Market...

DNTH : 115.54 (+0.59%)
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory...

DNTH : 115.54 (+0.59%)
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms ...

DNTH : 115.54 (+0.59%)
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 115.54 (+0.59%)
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 115.54 (+0.59%)
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

DNTH : 115.54 (+0.59%)
Stocks Settle Sharply Lower on Escalating Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June...

ALK : 42.41 (-3.70%)
GOOGL : 344.20 (+0.06%)
MPC : 366.21 (+2.24%)
AAPL : 310.03 (+1.45%)
FDXF : 139.23 (-3.19%)
TSLA : 336.87 (-0.72%)
FANG : 210.02 (+1.81%)
STX : 903.68 (-9.16%)
WDC : 496.16 (-7.43%)
AMD : 484.39 (-4.27%)
SPY : 767.45 (-0.68%)
META : 543.67 (-4.45%)
Stocks Resume Decline as Chipmakers and AI Companies Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures...

ALK : 42.41 (-3.70%)
MPC : 366.21 (+2.24%)
FDXF : 139.23 (-3.19%)
FANG : 210.02 (+1.81%)
WDC : 496.16 (-7.43%)
AMD : 484.39 (-4.27%)
SPY : 767.45 (-0.68%)
ILMN : 188.29 (-2.51%)
SMMT : 12.82 (+0.31%)
MU : 940.76 (-7.02%)
AAL : 14.05 (-2.63%)
QQQ : 717.51 (-1.69%)
Stocks Fall on Weakness in Tech and Trucking Companies

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. June E-mini S&P futures...

SAIA : 368.92 (-4.23%)
ALK : 42.41 (-3.70%)
UAL : 118.72 (-2.90%)
MPC : 366.21 (+2.24%)
AVGO : 380.00 (-3.17%)
CVX : 205.74 (+1.50%)
HNGE : 88.24 (+0.42%)
CBRL : 58.18 (-1.46%)
FDXF : 139.23 (-3.19%)
$IUXX : 29,490.96 (-1.68%)
ARCB : 138.81 (-4.84%)
ZNU26 : 108-220 (+0.12%)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 115.54 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 121.09
2nd Resistance Point 118.69
1st Resistance Point 117.12
Last Price 115.54
1st Support Level 113.15
2nd Support Level 110.75
3rd Support Level 109.18

See More

52-Week High 116.89
Last Price 115.54
Fibonacci 61.8% 80.14
Fibonacci 50% 68.79
Fibonacci 38.2% 57.44
52-Week Low 20.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.